MX2010004625A - Nuevos derivados de 4(tetrazol-5-il)-quinazolina como agentes anticancerosos. - Google Patents

Nuevos derivados de 4(tetrazol-5-il)-quinazolina como agentes anticancerosos.

Info

Publication number
MX2010004625A
MX2010004625A MX2010004625A MX2010004625A MX2010004625A MX 2010004625 A MX2010004625 A MX 2010004625A MX 2010004625 A MX2010004625 A MX 2010004625A MX 2010004625 A MX2010004625 A MX 2010004625A MX 2010004625 A MX2010004625 A MX 2010004625A
Authority
MX
Mexico
Prior art keywords
tetrazol
quinazoline derivatives
novel
cancer agents
anti cancer
Prior art date
Application number
MX2010004625A
Other languages
English (en)
Inventor
Bhujanga Rao Adibhatla Kali Satya
Nannapaneni Venkaiah Chowdary
Durga Prasad Konakanchi
Subba Rao Pula
Lakshmi Ananthaneni
Muddasani Pulla Reddy
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MX2010004625A publication Critical patent/MX2010004625A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a los derivados de 4-(tetrazol-5-il)-quina zolina sustituidos de la fórmula-I, o las sales farmacéuticamente aceptables de los mismos, que poseen actividad antiproliferativa tales como actividad anticancerosa y son en consecuencia útiles en los métodos de tratamiento del cuerpo humano o animal. La invención también se refiere a los procesos para la fabricación de derivados de 4-(tetrazol-5-il)-quinazolina sustituidos, a las composiciones farmacéuticas que contienen el compuesto y a su uso en la fabricación de medicamentos para la producción de un efecto antiproliferativo en un animal de sangre caliente tal como un ser humano.
MX2010004625A 2007-10-29 2008-10-28 Nuevos derivados de 4(tetrazol-5-il)-quinazolina como agentes anticancerosos. MX2010004625A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2445CH2007 2007-10-29
PCT/IN2008/000708 WO2009057139A2 (en) 2007-10-29 2008-10-28 Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents

Publications (1)

Publication Number Publication Date
MX2010004625A true MX2010004625A (es) 2010-05-20

Family

ID=40433677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004625A MX2010004625A (es) 2007-10-29 2008-10-28 Nuevos derivados de 4(tetrazol-5-il)-quinazolina como agentes anticancerosos.

Country Status (15)

Country Link
US (1) US8080558B2 (es)
EP (1) EP2220054A2 (es)
JP (1) JP2011502141A (es)
KR (1) KR20100087185A (es)
CN (1) CN101878203A (es)
AU (1) AU2008320342B2 (es)
CA (1) CA2703767A1 (es)
EA (1) EA018716B1 (es)
GE (1) GEP20125603B (es)
MX (1) MX2010004625A (es)
MY (1) MY150054A (es)
NZ (1) NZ585357A (es)
UA (1) UA101168C2 (es)
WO (1) WO2009057139A2 (es)
ZA (1) ZA201002807B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130729B (zh) * 2011-12-05 2015-07-15 齐鲁制药有限公司 一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
CN102993114B (zh) * 2012-10-11 2015-08-12 南通市华峰化工有限责任公司 一种1h-四唑-5-乙酸的生产方法
CN103204817B (zh) * 2013-04-16 2018-03-27 江西师范大学 4‑氰基喹唑啉衍生物的制备方法
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CN107406430B (zh) * 2015-03-20 2019-04-26 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
WO2021083347A1 (zh) * 2019-11-01 2021-05-06 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐、或其药物组合物的用途
CN114437041B (zh) * 2022-02-25 2023-11-10 湖北科技学院 一类具有抗肿瘤活性的4-四唑基取代-3，4-二氢喹唑啉衍生物及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800039A (en) * 1970-10-21 1974-03-26 Mead Johnson & Co Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines
JPH078851B2 (ja) 1985-07-29 1995-02-01 鐘淵化学工業株式会社 ３−フエニルチオメチルスチレン誘導体
US4971996A (en) 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors
AU632992B2 (en) 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
DE3917982A1 (de) 1989-06-02 1990-12-06 Behringwerke Ag Verwendung von xylanpolyhydrogensulfaten zur therapie von zellproliferations-bedingten erkrankungen
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5932574A (en) 1995-04-27 1999-08-03 Zeneca Limited Quinazoline derivatives
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PL190489B1 (pl) 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
EP0912572B1 (en) 1996-07-13 2003-01-15 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
BR0014116A (pt) 1999-09-21 2002-05-21 Astrazeneca Ab Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
GB0002040D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ATE402164T1 (de) * 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
KR20050042055A (ko) 2001-11-03 2005-05-04 아스트라제네카 아베 항종양제로서의 퀴나졸린 유도체
EP1471910A2 (en) * 2002-01-17 2004-11-03 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1567506A4 (en) 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
PT2049502E (pt) * 2006-07-28 2012-04-02 Novartis Ag Quinazolinas 2,4-substituídas como inibidores da lípido cinase

Also Published As

Publication number Publication date
ZA201002807B (en) 2011-07-27
AU2008320342A2 (en) 2010-09-02
WO2009057139A2 (en) 2009-05-07
KR20100087185A (ko) 2010-08-03
EA201070543A1 (ru) 2010-12-30
GEP20125603B (en) 2012-08-10
AU2008320342A1 (en) 2009-05-07
CA2703767A1 (en) 2009-05-07
CN101878203A (zh) 2010-11-03
MY150054A (en) 2013-11-29
WO2009057139A3 (en) 2009-09-24
AU2008320342B2 (en) 2012-07-26
NZ585357A (en) 2012-02-24
EP2220054A2 (en) 2010-08-25
US8080558B2 (en) 2011-12-20
JP2011502141A (ja) 2011-01-20
UA101168C2 (ru) 2013-03-11
EA018716B1 (ru) 2013-10-30
US20100261740A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
TW200736234A (en) Chemical compounds
MX2007008924A (es) Compuestos quimicos.
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
MX2009004908A (es) Compuestos quimicos.
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
MY150054A (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
WO2006067445A3 (en) Csf-1r kinase inhibitors
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
TW200634003A (en) Chemical compounds
TW200621259A (en) Chemical compounds
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
IN2014DN03206A (es)
TW200621730A (en) Chemical compounds
UA98961C2 (uk) Похідні піразинону та їх застосування у лікуванні легеневих захворювань
MX343706B (es) Derivados heterocíclicos novedosos.
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
MX2011009847A (es) Agentes antihelminticos y su uso.
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
WO2008068507A3 (en) 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
MX339644B (es) Sales de xantilio 3,6-disustituidas.
MX2011008899A (es) Nuevas orto-aminoamidas para el tratamiento del cancer.
WO2013040227A3 (en) Therapeutic compounds